ABSTRACT
The prevalence of iron deficiency anaemia is a significant issue worldwide, affecting individuals of all ages and often associated with inadequate iron bioavailability. Despite the use of ferrous salt supplements to address anaemia, their limited bioaccessibility and bioavailability in human GIT and adverse impact on food properties remain significant challenges. Hence, this study aims to explore the iron chelation mechanism of an exopolysaccharide EPSKar1 to enhance iron bioaccessibility, bioavailability, and anti-anaemic effects using cell culture and an anaemic rat model. EPSKar1 was extracted from Lacticaseibacillus rhamnosus Kar1 and complexed with FeSO4 to form "EPSKar1-iron". This novel complex, besides being bio-accessible after in vitro gastric digestion, demonstrated 61.27 ± 1.96% iron bioavailability to the Caco-2 cells. In line with these in vitro findings, intragastric administration of the EPSKar1-iron complex to anaemic Wistar rats at 25 and 50 mg per kg body weight significantly restored blood haemoglobin levels and re-established the morphological features of red blood cells. Furthermore, the apparent digestibility co-efficient and iron uptake improved significantly without adversely affecting the serum biochemical parameters in these anaemic rats. The levels of iron-transport proteins including serum transferrin and ferritin in tissue and plasma have increased remarkably upon oral administration of EPSKar1-iron at a higher dose of 50 mg per kg body weight. Oral supplementation of EPSKar1-iron did not foster adverse histological changes in the liver, kidneys, and spleen. In fact, the treatment with the EPSKar1-iron complex had a restitution effect on the tissue architecture, thereby ameliorating the tissue lesions. These findings collectively indicate that the EPSKar1-iron complex shows nutraceutical potential in enhancing the bioavailability of iron and could be a promising approach to tackle iron deficiency anaemia.
Subject(s)
Anemia, Iron-Deficiency , Anemia , Humans , Rats , Animals , Iron/metabolism , Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/metabolism , Rats, Wistar , Biological Availability , Caco-2 Cells , Anemia/drug therapy , Hemoglobins/metabolismABSTRACT
Two simple, rapid and sensitive extractive spectrophotometric methods have been developed for the assay of ceterizine hydrochloride (CTZH) in bulk drug and in pharmaceutical preparations. These methods are based on the formation of chloroform soluble complexes between CTZH with bromocresol purple (BCP) or bromophenol blue (BPB) in Walpole buffer of pH 2.64 with an absorption maximum at 409 nm and at 414 nm for BCP and BPB, respectively. Reaction conditions were optimised to obtain the maximum colour intensity. The absorbance was found to increase linearly with increase in concentration of CTZH, which was corroborated by the calculated correlation coefficient value (0.9991-0.9995). The system obeyed Beer's law in the range of 1-16 and 1.5-21 microl x ml(-1) for BCP and BPB, respectively. The various analytical parameters have been evaluated. The results obtained by the proposed methods were statistically compared by means of students t-test and by the variance ratio, F-test with those of the reported method and have shown to be in excellent agreement with the reported method.
Subject(s)
Anti-Allergic Agents/analysis , Cetirizine/analysis , Pharmaceutical Preparations/chemistry , Artifacts , Bromcresol Purple/chemistry , Bromphenol Blue/chemistry , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
A simple, rapid and sensitive spectrophotometric method for the assay of certain adrenergic drugs, [pyrocatechol (PC), levodopa (LD), methyldopa (MD) and dopamine (DP)] is described. The method involves the oxidation of o-dihydroxybenzene derivatives by K2CrO4 followed by oxidative coupling with sulfanilic acid (SPA), leading to the formation of a red or violet colored product having maximum absorbance at 490-495 nm for LD, MD and DP or at 560 nm for PC. This method has been successfully applied to the determination of LD, MD and DP in tablets and injections of pharmaceutical preparation. The common excipients do not interfere with the proposed method. A statistical comparison of these results with those of a reported method shows good agreement and indicates no significant difference in precision.
